



国内版

国际版

Prevention of Macrovascular Complications in Patients with Type 2 Diabetes Melli



All

Images

Videos

翻译成中文

关闭取词

19,200 Results

Any time ▾

Cardiovascular Complications in Diabetes | Diabetes Care

care.diabetesjournals.org/content/31/Supplement_2/S215 ▾

Feb 01, 2008 · THE PATIENT WITH DIABETES IN THE GENERAL PRACTITIONER'S OFFICE—. Data from the U.S. show that 9.3% of the population has diabetes (6.5% diagnosed and 2.8% undiagnosed) and an additional 26.0% has impaired fasting glucose, totaling 35.3% (73.3 million) with either diabetes or impaired fasting glucose (5).

Cited by: 87

Author: Alin O. Stirban, Diethelm Tschoepe

Publish Year: 2008

Type 2 diabetes: postprandial hyperglycemia and increased ...

www.ncbi.nlm.nih.gov › ... › Vasc Health Risk Manag › v.6; 2010

Abstract. Hyperglycemia is a major risk factor for both the microvascular and macrovascular complications in patients with type 2 diabetes. This review summarizes the cardiovascular results of large outcomes trials in diabetes and presents new evidence on the role of hyperglycemia, with particular emphasis on postprandial hyperglycemia,...

Cited by: 88

Author: Ajikumar V Aryangat, John E Gerich

Publish Year: 2010

Microvascular and Macrovascular Complications of Diabetes ...

clinical.diabetesjournals.org/content/26/2/77 ▾

Apr 01, 2008 · Macrovascular Complications of Diabetes. Studies in type 1 diabetes have shown that intensive diabetes control is associated with a lower resting heart rate and that patients with higher degrees of hyperglycemia tend to have a higher heart rate, which is associated with higher risk of CVD. 22 Even more conclusively,...

Cited by: 1162

Author: Michael J. Fowler

Publish Year: 2008

Name of Journal: *World Journal of Diabetes*

Manuscript NO: 46649

Manuscript Type: MINIREVIEWS

**Prevention of macrovascular complications in patients with type 2 diabetes mellitus:
Review of cardiovascular safety and efficacy of newer diabetes medications**

Ravi Kant, Kashif M Munir, Arshpreet Kaur, Vipin Verma

Abstract

Lack of conclusive beneficial effects of strict glycemic control on macrovascular complications has been very frustrating for clinicians involved in care of patients with diabetes mellitus (DM). Highly publicized controversy surrounding cardiovascular (CV) safety of rosiglitazone resulted in major changes in United States Food and Drug Administration (FDA) policy in 2008 regarding approval process of new antidiabetic

Match Overview

1	Internet 61 words crawled on 22-Nov-2018 www.nejm.org	1%
2	Crossref 53 words Dimitrios Sfairopoulos, Stavros Liatis, Stelios Tigas, Evar... elos Liberopoulos. "Clinical pharmacology of glucagon-like	1%
3	Internet 44 words crawled on 24-Oct-2017 bjcardio.co.uk	1%
4	Internet 40 words crawled on 29-Oct-2017 www.diabetesincontrol.com	1%
5	Internet 39 words crawled on 14-Dec-2018 www.tsoc.org.tw	1%
6	Crossref 37 words André J. Scheen. "Cardiovascular outcome studies in type 2 diabetes : comparison between SGLT2 inhibitors and G...	1%
7	Internet 37 words crawled on 01-Oct-2016 www.ncbi.nlm.nih.gov	1%
8	Internet 26 words crawled on 02-May-2016 journal.publications.chestnet.org	1%
9	Crossref 25 words Bassant Orabi, Rasha Kaddoura, Amr S. Omar, Cornelia C arr, Abdulaziz Alkhulaifi. "Molecular and clinical roles of ir...	1%
10	Crossref 25 words Maria Isabel del Olmo-Garcia, Juan Francisco Merino-Torre	1%

[国内版](#)[国际版](#)

Prevention of macrovascular complications in patients with type 2 diabetes mellitu

[All](#)[Images](#)[Videos](#)[翻译成中文](#)[关闭取词](#)

19,800 Results

Any time ▾

Cardiovascular Complications in Diabetes | Diabetes Care

care.diabetesjournals.org/content/31/Supplement_2/S215 ▾

Feb 01, 2008 · THE **PATIENT WITH DIABETES** IN THE GENERAL PRACTITIONER'S OFFICE—. Data from the U.S. show that **9.3%** of the population has **diabetes** (**6.5% diagnosed and 2.8%** undiagnosed) and an additional **26.0%** has impaired fasting glucose, totaling **35.3%** (**73.3 million**) with either **diabetes** or impaired fasting **glucose** (**5**).

Screening, Prevention, Counseling, and Treatment for the ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1497162>

Prevention and treatment of the **complications** of **diabetes mellitus** have the potential to improve quality of life and increase life expectancy. 3 The rate **of cardiovascular** disease is markedly elevated among **patients with type II diabetes**, leading to an increased mortality rate compared with the general population. 4, 5 In addition ...

Cited by: 119

Author: Sandeep Vijan, Deryth L. Stevens, William ...

Publish Year: 1997

Microvascular and Macrovascular Complications of Diabetes ...

clinical.diabetesjournals.org/content/26/2/77 ▾

Apr 01, 2008 · **Macrovascular Complications of Diabetes**. Studies in **type 1 diabetes** have shown that **intensive diabetes control** is associated with a lower resting heart rate and that **patients** with higher degrees of **hyperglycemia** tend to have a higher heart rate, which is associated with higher **risk of CVD**. 22 Even more conclusively,...

Published in: [Clinical Diabetes](#) · 2008

Authors: [Michael J Fowler](#)

Reducing cardiovascular risk in patients with type 2 ...

<https://www.sciencedirect.com/science/article/pii/S1357303918302834>

The Empagliflozin **Cardiovascular** Outcome Event Trial in **Type 2 Diabetes Mellitus Patients** (EMPA-REG) involved 7020 T2DM **patients** with an average age of 63 years. All participants had established **cardiovascular** disease, and were randomly assigned different doses of empagliflozin or placebo in addition to their standard diabetic therapy.

Author: Azfar G. Zaman, Azfar G. Zaman, Azfa...

Publish Year: 2019